

AbbVie Inc. (ABBV)

\$229.98 (Stock Price as of 12/26/2025)

Price Target (6-12 Months): **\$240.00**

Long Term: 6-12 Months | **Zacks Recommendation:** **Neutral**
(Since: 07/12/22)
Prior Recommendation: Underperform

Short Term: 1-3 Months | **Zacks Rank:** (1-5) **3-Hold**
Zacks Style Scores: VGM: D
Value: C | Growth: C | Momentum: F

Summary

AbbVie has successfully navigated Humira's loss of exclusivity (LOE) by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications. These should support top-line growth in the next few years. Its oncology and neuroscience drugs are also contributing to top-line growth. AbbVie is returning to robust revenue growth in 2025, which is just the second year following the U.S. Humira LOE. It has been on an acquisition spree in the past couple of years to bolster its early-stage pipeline that should drive long-term growth. However, the company faces several headwinds like Humira LOE impact, increasing competitive pressure on Imbruvica and continued macro headwinds for Aesthetics. AbbVie's shares have outperformed the industry in the past one year.

Data Overview

52 Week High-Low	\$244.81 - \$164.39
20 Day Average Volume (sh)	5,186,824
Market Cap	\$406.5 B
YTD Price Change	29.4%
Beta	0.36
Dividend / Div Yld	\$6.92 / 2.9%
Industry	Large Cap Pharmaceuticals
Zacks Industry Rank	Bottom 25% (182 out of 243)


Last EPS Surprise	5.1%
Last Sales Surprise	1.2%
EPS F1 Est- 4 week change	0.0%
Expected Report Date	01/30/2026
Earnings ESP	2.0%

P/E TTM	24.3
P/E F1	21.6
PEG F1	1.3
P/S TTM	6.8

Price, Consensus & Surprise⁽¹⁾



Sales and EPS Growth Rates (Y/Y %)⁽²⁾



Sales Estimates (millions of \$)⁽²⁾

	Q1	Q2	Q3	Q4	Annual*
2026	14,721 E	16,793 E	17,350 E	17,758 E	66,622 E
2025	13,343 A	15,423 A	15,776 A	16,312 E	60,854 E
2024	12,310 A	14,462 A	14,460 A	15,102 A	56,334 A

EPS Estimates⁽²⁾

	Q1	Q2	Q3	Q4	Annual*
2026	2.94 E	3.58 E	3.72 E	3.68 E	13.92 E
2025	2.46 A	2.97 A	1.86 A	3.35 E	10.64 E
2024	2.31 A	2.65 A	3.00 A	2.16 A	10.12 A

*Quarterly figures may not add up to annual.

(1) The data in the charts and tables, except the estimates, is as of 12/26/2025.

(2) The report's text, the analyst-provided estimates, and the price target are as of 12/24/2025.

Overview

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for \$63 billion in May 2020. The deal transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product, which has lost patent protection in Europe as well as the United States. Its new immunology drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.


AbbVie came into existence on Jan 1, 2013, after Abbott Laboratories divested its pharmaceutical division. In May 2020, AbbVie acquired Allergan for about \$20 billion. In June 2016, AbbVie acquired cancer drugmaker, Stemcentrx in a cash-and-stock deal worth \$5.8 billion. In February 2024, AbbVie acquired ImmunoGen, which added the latter's antibody-drug conjugate (ADC) for ovarian cancer, Elahere, to its oncology portfolio. In August 2024, it acquired neuroscience drugmaker Cerevel Therapeutics.

AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics and eye care.

Humira is approved for several autoimmune diseases like rheumatoid arthritis (RA), active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica (hematological cancers) became part of the company's portfolio following the Pharmacyclics acquisition.

Other key drugs include Venclexta (venetoclax) (hematological malignancies), Botox Cosmetic (aesthetic use), Botox Therapeutics (neuroscience indications), Vraylar (schizophrenia and bipolar I disorder), Skyrizi (plaque psoriasis, psoriatic arthritis, ulcerative colitis and Crohn's disease) and Rinvoq (RA, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthritis, Crohn's disease, ulcerative colitis and giant cell arteritis). The company also has partnerships with companies like Roche and J&J.

AbbVie reported total sales of \$56.3 billion for 2024, up 3.7% on a reported basis and 4.6% on an operational basis. Humira, Skyrizi and Rinvoq accounted for 15%, 20.8% and 10.6%, respectively, of AbbVie's total revenues in 2024. Imbruvica accounted for around 6%, while Botox (cosmetic and therapeutic) accounted for 10.7% of AbbVie's total revenues in 2024.



Reasons To Buy:

▲ **Successful New Drugs – Skyrizi and Rinvoq:** AbbVie launched Skyrizi and Rinvoq across Humira's major indications, plus a distinct new indication, atopic dermatitis. With approvals for many new indications, sales of these drugs have successfully replaced the blockbuster drug Humira, which started facing generic erosion in the United States from 2023. Skyrizi and Rinvoq demonstrated compelling head-to-head data against several novel therapies in clinical studies, giving them a competitive advantage

The drugs have contributed meaningful revenues, including \$7.7 billion in 2022, \$11.7 billion in 2023, \$17.7 billion in 2024 and \$18.5 billion year to date. Skyrizi sales are now annualizing at almost \$18 billion and Rinvoq at over \$8 billion. AbbVie expects to outperform its target of combined sales of Skyrizi and Rinvoq to be more than \$25 billion in 2025 and more than \$31 billion by 2027 (Skyrizi: more than \$20 billion; Rinvoq: more than \$11 billion).

Skyrizi and Rinvoq are seeing strong performance across all their approved indications, especially in the popular inflammatory bowel disease (IBD) space, which includes two conditions, ulcerative colitis ("UC") and Crohn's disease ("CD"). AbbVie expects Skyrizi and Rinvoq to double their combined sales in IBD in 2025.

Strong immunology market growth, market share gains and momentum from new indications, such as the recent launch of Skyrizi in UC, as well as the potential for five new indications for Rinvoq over the next few years, are expected to drive these drugs' growth. AbbVie expects to file a regulatory submission for Rinvoq for the alopecia areata indication soon. In addition, phase III data with Rinvoq in hidradenitis suppurativa and systemic lupus erythematosus are expected in 2026. AbbVie believes that the next wave of potential approvals in Rinvoq could add roughly \$2 billion to peak-year sales for the product.

In September 2025, AbbVie settled a patent litigation with all generic manufacturers for Rinvoq, which extended the drug's patent exclusivity by four years to 2037.

Our estimates for Skyrizi and Rinvoq suggest a CAGR of 28.3% and 24.4%, respectively, over the next three years.

Meanwhile, new migraine drugs, Ubrovelvy and Qulipta/Aquipta, represent a combined \$3 billion-plus peak sales opportunity.

Boosted by its new product launches, AbbVie expects to return to robust mid-single-digit revenue growth in 2025 with a high single-digit CAGR through 2029, as the company has no significant LOE events for the rest of this decade. A substantial portion of this growth is expected to be driven by the robust performance of Skyrizi and Rinvoq. In the first nine months of the year, its total revenues rose 8.2%, in line with its expectation of mid-single-digit revenue growth.

AbbVie shares have risen 27.1% in the past one year against the industry's increase of 16.1% in the same time frame.

▲ **Growing Oncology Portfolio:** AbbVie has built a substantial oncology franchise with Imbruvica and Venclexta. Its oncology segment generated combined revenues of \$6.6 billion in 2022, \$5.9 billion in 2023, \$6.6 billion in 2024 and \$5.0 billion in the first nine months of 2025, up 2.7% year over year.

AbbVie is studying Venclyxto/Venclexta to expand the label for the approved indications — acute myeloid leukemia and chronic lymphocytic leukemia — and broaden into other hematologic malignancies like acute lymphocytic leukemia and myelodysplastic syndrome. Label expansion approvals in the past couple of years have expanded the eligible patient population of Venclexta significantly, which is boosting sales of the drug. AbbVie expects Venclexta peak revenues to approach \$5 billion.

AbbVie and partner Genmab's Epkinly/Tepkinly (formerly epcoritamab) was approved for relapsed or refractory (r/r) third-line diffuse large B-cell lymphoma (DLBCL) in 2023 and for third-line r/r follicular lymphoma in 2024. Phase III studies are ongoing on Epkinly in earlier lines of DLBCL and FL. Emrelis (previously Teliso-V), a promising c-Met ADC was approved in the United States for previously treated non-squamous non-small cell lung cancer with high c-Met expression in May 2025. Elahere was added to AbbVie's oncology portfolio with the February 2024 acquisition of Immunogen. These three new drugs have strengthened AbbVie's oncology franchise. Elahere and Epkinly both delivered double-digit revenue growth in the first nine months of 2025.

AbbVie is strengthening its portfolio of oncology medicines with the addition of ADCs, which are being considered a disruptive innovation in the pharmaceutical industry. ADCs will allow better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors. The company now has two ADCs in the commercial portfolio (i.e., Elahere and Emrelis) and two additional ADCs in late-stage development [Temab-A (metastatic colorectal cancer – phase III, gastroesophageal cancer and NSCLC – phase II), pivekimab sunirine (blastic plasmacytoid dendritic cell neoplasm –under review in the United States, acute myeloid leukemia – phase II), plus some others in early-stage development.

Another key candidate in its oncology pipeline is etentamig/ABBV-383, a BCMA CD3 bispecific being developed for relapsed/refractory multiple myeloma.

Our estimates for AbbVie's oncology portfolio suggest a CAGR of 3.3% over the next three years.

▲ **Promising Pipeline:** AbbVie has been consistently increasing its R&D spend and has several promising R&D programs with the potential to drive long-term growth. This includes next-generation approaches in immunology, a focus on bispecifics and ADCs, as well as innovative

AbbVie's Skyrizi and Rinvoq, are performing extremely well, bolstered by approval in new indications, which should support top-line growth in the next few years.

therapies for neuropsychiatric and neurodegenerative disorders.

Promising candidates include Rinvoq/upadacitinib (systemic lupus erythematosus, hidradenitis suppurativa, vitiligo, alopecia areata and takayasu arteritis - phase III), lutikizumab (hidradenitis suppurativa – phase III, ulcerative colitis and atopic dermatitis – phase II), brexsislocin (major depressive disorder – phase II) and tavapadon (once-daily oral treatment for Parkinson's disease – NDA filed in September 2025). Vraylar was approved for major depressive disorder in the United States in December 2022, which boosted the product's sales. In November 2024, AbbVie gained approval for Vyalev, a transformative therapy for treating advanced Parkinson's disease. The initial international launch uptake of Vyalev has been encouraging. Studies are also ongoing to evaluate new indications for Botox and the Juvederm collection of fillers.

▲ **Collaborations and Agreements to Strengthen Pipeline:** We are positive about AbbVie's efforts to strengthen its pipeline. The company has been actively pursuing partnership deals and collaborations for candidates across several therapeutic areas, including immunology, oncology, aesthetics, neuroscience, eye care and women's health. Some partners include Roche (Venclexta – oncology) and J&J (Imbruvica – cancer). In 2020, AbbVie signed an oncology deal with Genmab to jointly develop and commercialize Genmab's three investigational bispecific antibody therapeutics, including Epkinly/epcoritamab.

AbbVie has been on an acquisition spree in the past couple of years to bolster the early-stage pipeline that should drive long-term growth. Particularly, it is signing several M&A deals in the immunology space, its core area, while also signing some early-stage deals in oncology and neuroscience areas. AbbVie has executed more than 30 M&A transactions since the beginning of 2024. A key deal is the April 2025 licensing agreement with Denmark's Gubra to develop GUB014295 (ABBV-295), a long-acting amylin analog for the treatment of obesity, which marks AbbVie's entry into the popular obesity space. AbbVie plans to invest further in obesity. A recent acquisition was the August 2025 acquisition of Capstan Therapeutics, which added Capstan's lead asset, CPTX2309 (ABBV-619) — a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy — to AbbVie's immunology pipeline.

▲ **Favorable Debt Profile:** As of Sept. 30, 2025, AbbVie had \$63.0 billion in long-term debt and short-term debt/obligations of \$5.77 billion on its balance sheet. Cash and cash equivalents totaled approximately \$5.67 billion. Though the company is highly leveraged, it enjoys decent ratings from credit rating agencies.

Moody's has an A3 senior unsecured long-term rating with a positive outlook and the Prime-2 short-term rating on AbbVie. S&P Global Ratings has an issuer credit rating of A- on AbbVie with a stable outlook, which means the company has adequate capacity to meet its financial commitments. However, adverse economic conditions may weaken this capacity.

Reasons To Sell:

▼ **Humira Biosimilars Eroding Sales:** Several companies have made biosimilar versions of Humira. In 2022, Humira accounted for around 37% of AbbVie's sales. Humira biosimilars were launched in the EU in October 2018 and have rapidly eroded international sales from the branded drug since then. In the United States, Humira lost exclusivity in January 2023 and Amgen was the first company to launch its Humira biosimilar. Thereafter, several other biosimilar versions of Humira were launched in the United States. Humira biosimilars significantly eroded the drug's sales in 2024, with the decline being sharper in 2025 and expected to continue to decline in 2026 as more plans excluded branded Humira and moved to exclusive biosimilar contracts. Humira sales declined more than 50% in the first nine months of 2025.

Our estimates for Humira suggest a CAGR decline of 36.7% over the next three years.

▼ **Aesthetics Segment Continues to Struggle:** AbbVie is seeing declining sales of its Aesthetics unit due to continued macro challenges and weakened consumer sentiment. Global sales of the aesthetics portfolio declined 0.6% in 2024 and 7.4% in the first nine months of 2025.

Continued macro challenges and low consumer sentiment, especially in the United States, with concerns about the economy and inflation weighing on discretionary spending, are hurting aesthetics sales. Juvederm sales declined 14.6% in 2024 and 16.7% in the first nine months of 2025. Botox Cosmetics sales declined 7.4% in the first nine months of 2025. AbbVie now expects category growth to be below previous expectations.

On the third-quarter conference call, AbbVie lowered its expectation for the Aesthetics business from \$5.1 billion to \$4.9 billion due to greater-than-expected market softness globally.

Our estimates for the Aesthetics unit suggest around 6% year over year decline in 2025.

▼ **Pipeline and Regulatory Setbacks:** While we believe that AbbVie has an impressive pipeline, we note that clinical development involves a high degree of risk. Gaining approval for pipeline candidates has become more difficult given the tough regulatory environment. Development and regulatory setbacks for late-stage pipeline candidates would be a major disappointment for the company.

In November 2024, AbbVie's two registration-enabling phase II studies on emraclidine, its once-daily, oral candidate for treating schizophrenia, failed to meet their primary endpoints. Emraclidine was added to AbbVie's pipeline with the acquisition of Cerevel and was a key reason for AbbVie to buy the company, thus bringing into question the viability of the deal.

In August 2019, AbbVie discontinued the development of rovalpituzumab tesirine or Rova-T due to poor/no survival benefit observed for patients treated with Rova-T in three studies. Rova-T was added to AbbVie's portfolio, following the acquisition of Stemcentrx in June 2016. The failure of Rova-T brought into question the viability of the Stemcentrx deal.

In May 2019, a phase III study evaluating depatuxizumab mafodotin (Depatux-M) failed to show any survival benefit in patients with newly diagnosed glioblastoma, an aggressive form of brain cancer. As a result, AbbVie stopped enrollment in all ongoing Depatux-M studies.

The FDA issued two complete response letters to its Parkinson's disease pipeline candidate, ABBV-951 in 2023/2024.

▼ **Macroeconomic Headwinds:** Uncertain macroeconomic conditions, including the risk of inflation, a slowing labor market and instability in the financial system, along with escalating geopolitical tensions in various parts of the world, have increased broader economic woes.

Uncertainty around tariffs and trade protection measures in the United States remains. President Trump has threatened to impose a 100% tariff on pharmaceutical imports unless a company builds pharmaceutical plants in the United States. Trump's repeated threats to impose tariffs on pharmaceutical imports are aimed at pushing American pharma companies to shift pharmaceutical production back to the United States, primarily from European and Asian countries.

Trump is trying to implement the Most Favored Nation (MFN) pricing policy. The goal of this proposed policy is to ensure that U.S. consumers pay the same price for some prescription drugs as in some selected comparable developed nations. Such a policy, if implemented, can hurt prices and reimbursement of some of the company's drugs.

▼ **Intense Competition for Key Products:** AbbVie's immunology products compete with anti-TNF products, JAK inhibitors and other competitive products intended to treat several diseases. AbbVie's oncology products compete with BTK inhibitors. U.S. sales of Imbruvica are being hurt by rising competition from novel oral treatments.

Humira's biosimilar erosion, increasing competitive pressure on Imbruvica and slowing sales of its aesthetics franchise are headwinds.

Last Earnings Report

Q3 Earnings & Sales Beat, 2025 EPS View Raised

AbbVie reported third-quarter 2025 adjusted EPS of \$1.86, which beat the Zacks Consensus Estimate of \$1.77. The reported figure also exceeded the company's guidance of \$1.74-\$1.78. Earnings declined 38.0% year over year, mainly due to higher IPR&D charges incurred during the quarter. Adjusted EPS included \$1.50 per share of unfavorable impact from acquired IPR&D expense.

Revenues of \$15.78 billion beat the Zacks Consensus Estimate of \$15.59 billion as well as the company's guidance of \$15.5 billion. Sales rose 9.1% year over year on a reported basis and 8.4% on an operational basis.

Revenues in the quarter were driven by the continued strength of Rinvoq and Skyrizi. The company's top line also benefited from double-digit revenue growth from its neuroscience franchise, supported by newer assets like Ubrovelvy, Qulipta and Vyalev. However, overall growth was partially offset by Humira's continued generic erosion and weak aesthetics sales.

Skyrizi and Rinvoq generated combined sales growth of more than 40%.

Sales of AbbVie's ex-Humira drugs rose more than 20% (on a reported basis) in the quarter, above company's expectations, driven by Skyrizi, Rinvoq and neuroscience.

Quarter in Details

Global net revenues from the immunology portfolio were \$7.9 billion, up 11.2% on an operational basis.

In immunology, Skyrizi registered sales of \$4.71 billion, up 46.0% on an operational basis year over year, reflecting strong volume growth and continued market share gains. Skyrizi sales beat both the Zacks Consensus Estimate of \$4.56 billion and our model estimate of \$4.54 billion.

Rinvoq registered sales of \$2.18 billion, up 34.1% on an operational basis year over year, primarily driven by market share gains across all approved indications. Rinvoq's sales beat the Zacks Consensus Estimate and our model estimate, both pegged at \$2.16 billion.

Across IBD, Skyrizi and Rinvoq continue to capture a significant share. In Crohn's disease, Skyrizi and Rinvoq have together gained in-play share leadership in 12 countries. In UC, Skyrizi and Rinvoq together hold in-play share leadership in more than 10 key markets. In Crohn's, while Skyrizi and Rinvoq are capturing roughly 50% of newer switching patients across all lines of therapy, in UC, they are capturing nearly 33% of the newer switching patients.

For other indications, Skyrizi is gaining share across our key markets in psoriasis while Rinvoq is also delivering strong prescription growth in rheumatoid arthritis. Rinvoq is also seeing a nice ramp-up for the newly approved giant cell arteritis indication, where Rinvoq now has full formulary coverage

In 2025, Skyrizi revenues are expected to be around \$17.3 billion, up from the previous expectation of \$17.1 billion due to share gains in psoriasis and IBD. Rinvoq sales are expected to be approximately \$7.9 billion.

Humira recorded a sales decline of 55.7% to \$993 million for the third quarter due to biosimilar competition. Sales in the United States declined 65% to \$619 million, while ex-U.S. market sales were down 20.5% to \$374 million. Humira sales missed the Zacks Consensus Estimate of \$1.15 billion and our model estimate of \$1.16 billion.

AbbVie expects Humira's access in the United States to continue to decrease through the rest of 2025 and in 2026 as more plans select exclusionary formularies for existing patients. However, this will be partially offset by price gains from those contract changes.

AbbVie's oncology/hematology sales fell 1.3% to \$1.68 billion in the quarter, as rising Venclexta sales and contributions from Elahere and Epkinly were offset by declining Imbruvica sales. The metric missed both the Zacks Consensus Estimate and our model estimate of \$1.69 billion and \$1.71 billion, respectively.

Third-quarter net revenues from Imbruvica totaled \$706 million, down 14.8%. Though this figure beat our model estimate of \$703 million, it missed the Zacks Consensus Estimate of \$708 million.

U.S. sales of Imbruvica declined 17.9% to \$507 million, reflecting continued competitive pressure in CLL. AbbVie shares international profits earned from Imbruvica with J&J. AbbVie's share of profit from the drug's international sales declined 5.8% to \$199 million.

Venclexta generated revenues of \$726 million in the reported quarter, reflecting 4.9% growth, driven by strong demand, partially offset by unfavorable pricing. Venclexta sales beat the Zacks Consensus Estimate of \$712 million but missed our model estimate of \$727 million.

Epkinly sales, which comprise AbbVie's share of profit from U.S. revenues and product revenues from international markets, amounted to \$69 million in the quarter compared with \$70 million in the previous quarter.

Elahere revenues rose 22.4% to \$170 million. Sales of the drug missed both the Zacks Consensus Estimate of \$199 million and our model estimate of \$197 million.

FY Quarter Ending 12/31/2024

Earnings Reporting Date	Oct 31, 2025
Sales Surprise	1.20%
EPS Surprise	5.08%
Quarterly EPS	1.86
Annual EPS (TTM)	9.45

Sales from the neuroscience portfolio increased 19.6% to \$2.84 billion, driven by higher sales of Botox Therapeutic, Vraylar, and migraine drugs Ubrelvy and Qulipta. Neuroscience sales beat the Zacks Consensus Estimate and our model estimate of \$2.74 billion and \$2.73 billion, respectively.

In neuroscience, sales of Vraylar increased 6.7% to \$934 million, driven by growth in both MDD and bipolar disorders. Botox Therapeutic sales rose 15.8% to \$985 million.

Duodopa sales declined 17.3% to \$67.0 million. Sales of Ubrelvy totaled \$354 million, up 31.5%. Qulipta sales increased 63.1% to \$288 million.

Sales of Vyalev, the recently approved transformative therapy for advanced Parkinson's disease, totaled \$138 million, up 40.8% on a sequential basis, reflecting a strong global launch. While the uptake across international markets is encouraging, AbbVie expects expanded coverage in the United States soon, which should improve revenues in 2026.

In 2025, neuroscience global sales are expected to be \$10.7 billion, an increase of \$200 million from the prior expectation of \$10.5 billion.

AbbVie's aesthetics portfolio sales were down 4.2% to \$1.19 billion, which missed the Zacks Consensus Estimate of \$1.27 billion and our model estimate of \$1.30 billion. Botox Cosmetic sales fell 5.4% to \$637 million. Juvederm sales declined 3.2% to \$253 million.

Continued macro challenges in several markets, low consumer sentiment and inflationary concerns in the United States are hurting discretionary spending, causing a decline in aesthetics sales.

U.S. aesthetic sales were \$742 million, down 6.2% year over year due to challenging market conditions. Botox Cosmetic sales declined 8.4% due to decreased market share and consumer demand in the United States. Juvederm sales declined 7.5% due to decreased global demand.

International aesthetic sales were \$451 million, up 0.8% year over year on a reported basis. On an operational basis, sales declined 0.6%.

AbbVie lowered its expectation for its Aesthetics business from \$5.1 billion to \$4.9 billion due to greater-than-expected market softness globally.

Eye care portfolio sales declined 4.2% to \$509 million. Sales of Ozurdex, a key drug in the portfolio, fell 4.0% to \$117 million.

Among other key drugs, Mavyret rose 1% operationally to \$312 million. Linzess sales rose 39.1% to \$326 million.

Costs Discussion

Adjusted gross margin was 83.9% in the quarter. Adjusted SG&A expenses rose 2.6% year over year to \$3.41 billion. Adjusted R&D expenses amounted to \$2.26 billion, up 9.8%.

The adjusted operating margin was 30.9% in the quarter, which includes a 17% unfavorable impact from acquired IPR&D expense.

Ups Dividend

AbbVie's board of directors approved a 5.5% increase in its quarterly dividend from \$1.64 per share to \$1.73 per share, beginning with the dividend payable in February 2026. The dividend will be paid out on Feb. 17, 2026, to shareholders of record as of Jan. 16, 2026.

2025 Outlook

AbbVie raised its revenue and EPS guidance for 2025 for the third time this year, backed by strong momentum year to date.

The company expects adjusted EPS to be in the range of \$10.61-\$10.65, up from the previous guidance of \$10.38-\$10.58.

This guided range includes an impact of \$2.05 per share related to acquired IPR&D and milestones expense incurred so far in the year.

Total revenues are expected to be approximately \$60.9 billion, higher than the previous expectation of \$60.5 billion.

Adjusted gross margin is expected to be approximately 84% of sales. Adjusted R&D is expected to be approximately \$9 billion. Adjusted SG&A expense is expected to be approximately \$13.5 billion. Adjusted operating margin is expected to be approximately 41%, down from the previous expectation of approximately 45% due to the unfavorable impact of acquired IPR&D expense incurred through the third quarter.

Regarding Medicare price negotiations for Vraylar and Linzess, AbbVie said that those prices will not take effect until 2027 and so will not impact its 2026 guidance. The company is also not much concerned about it impacting its long-term guidance.

Fourth-Quarter 2025 Outlook

In the fourth quarter of 2025, adjusted earnings are expected to be between \$3.32 and \$3.36 per share. AbbVie expects net revenues of more than \$16.3 billion in the third quarter. Currency is expected to have a positive impact of around 1% on sales.

Recent News

DA Approval for Epkinly Combination in R/R Follicular Lymphoma – Nov 18

AbbVie announced that the FDA has approved expanded use of Epkinly for earlier lines of therapy in follicular lymphoma. The FDA has approved Epkinly in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (R/R FL) after at least one line of systemic therapy. The approval is based on results from the pivotal phase III EPCORE FL-1 study.

The safety profile of EPKINLY + R2 was consistent with previously known risks for epcoritamab and R2. Common adverse reactions included rash, infections, fatigue, injection-site reactions and cytokine release syndrome (CRS), mostly low grade. The prescribing information carries a boxed warning for serious CRS and immune effector cell–associated neurotoxicity syndrome (ICANS).

The approval marks the third indication for Epkinly and first-ever FDA approval for a bispecific combination therapy in lymphoma.

Epkinly is already approved for monotherapy use by the FDA for the treatment of R/R FL following two or more lines of systemic therapy. With the results of the confirmatory phase III EPCORE FL-1 study, the FDA has now converted the drug's earlier accelerated approval in follicular lymphoma to full approval. AbbVie said it plans to pursue regulatory filings in additional countries, and the EPCORE FL-1 data will be presented at the ASH annual meeting in December.

Positive Data from Phase III study on Rinvoq in Vitiligo – Oct. 29

AbbVie announced positive top-line results from two phase III studies evaluating Rinvoq (15 mg, once daily) in adults and adolescents with non-segmental vitiligo (NSV) — the most common form of the disease.

The studies met both co-primary endpoints at week 48, showing that treatment with Rinvoq led to significantly greater improvements in re-pigmentation compared to placebo. Approximately 20% of patients treated with RINVOQ achieved a 50% reduction in total body depigmentation (T-VASI 50), while about 24% achieved a 75% reduction in facial depigmentation (F-VASI 75) versus around 6% in the placebo groups.

Rinvoq also demonstrated statistically significant improvements in key secondary endpoints, including F-VASI 50, indicating that nearly half of the treated patients achieved at least 50% facial re-pigmentation compared to about 13% in the placebo groups. The safety profile was consistent with previous studies of Rinvoq across other indications, with the most common adverse events being upper respiratory infections, acne and nasopharyngitis. No new safety signals or major cardiovascular events were observed.

Use of Rinvoq in vitiligo is not yet approved by regulatory authorities. Rinvoq is already approved for several immune-mediated inflammatory diseases and continues to be evaluated for additional conditions, including vitiligo, alopecia areata and lupus.

Rinvoq Shows Superiority Over Humira in Rheumatoid Arthritis Study – Oct. 20

AbbVie announced positive top-line results from its phase IIIb/4 SELECT-SWITCH study evaluating Rinvoq (15 mg, once daily) versus Humira in adults with moderate-to-severe rheumatoid arthritis (RA) who did not respond adequately or were intolerant to a prior TNF inhibitor. The study met its primary endpoint, with Rinvoq demonstrating superiority in achieving low disease activity (DAS28-CRP ≤ 3.2) at week 12, as well as the ranked secondary endpoint of remission (DAS28-CRP < 2.6).

Results showed that 43.3% of patients treated with Rinvoq achieved low disease activity compared to 22.4% with Humira, while 28.4% reached remission versus 14.5% for Humira. The safety profile for Rinvoq was consistent with prior studies, with no new safety risks observed.

Full results from the SELECT-SWITCH study will be published in a medical journal and presented at an upcoming scientific meeting.

Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin – Oct 17

AbbVie closed its previously announced acquisition of Gilgamesh Pharmaceuticals' lead investigational compound, bretisilocin, a next-generation psychedelic drug candidate currently in phase II studies for major depressive disorder (MDD). AbbVie had previously announced the definitive agreement to acquire bretisilocin earlier this year.

Expands Rinvoq Indication for Inflammatory Bowel Disease – Oct 13

AbbVie announced that the FDA has approved a supplemental new drug application (sNDA) expanding the indication for Rinvoq (upadacitinib) in the treatment of moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

The updated label now allows Rinvoq to be used prior to tumor necrosis factor (TNF) blockers in patients for whom such treatments are clinically inadvisable, provided they have received at least one approved systemic therapy. Previously, Rinvoq was indicated only for patients who had an inadequate response or intolerance to one or more TNF blockers.

Positive Phase II Data for Botox in Upper Limb Essential Tremor

AbbVie announced positive top-line results from its phase II ELATE study evaluating onabotulinumtoxinA (Botox) for the treatment of upper limb essential tremor. The study met its primary endpoint, showing statistically significant improvement from baseline in the Tremor Disability Scale-Revised (TREDs-R) total unilateral score versus placebo at week 18, with reductions of -2.61 for Botox versus -1.61 for placebo ($p=0.029$). The study also achieved all six secondary endpoints.

Botox is not currently approved for the treatment of essential tremor.

Submits BLA to FDA for Pivekimab Sunirine (PVEK) to Treat Rare Blood Cancer – Sep 30

AbbVie announced that it has submitted a biologics license application (BLA) to the FDA seeking approval for pivekimab sunirine (PVEK), an investigational antibody-drug conjugate (ADC), for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) — a rare and aggressive blood cancer with limited treatment options.

The submission is based on data from the global Phase I/II CADENZA study.

Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease – Sep 26

AbbVie announced that it has submitted a regulatory filing with the FDA, which seeks approval for its investigational drug, tavapadon, as a once-daily oral treatment for Parkinson's disease (PD).

The FDA filing is supported by results from three late-stage studies — TEMPO-1, TEMPO-2 and TEMPO-3 — which demonstrated symptomatic improvement across a broad PD population. While TEMPO-1 and TEMPO-2 studies showed that tavapadon significantly reduced disease burden in early PD patients, TEMPO-3 results highlighted benefits when the drug was used as an add-on to levodopa, the current standard of care for PD symptoms.

If approved, tavapadon would represent AbbVie's second recent FDA clearance in the PD indication, further reinforcing its presence in the space. Last year in October, the FDA approved Vyalev as the first and only subcutaneous 24-hour continuous infusion of carbidopa and levodopa prodrugs to treat motor fluctuations in advanced PD.

Valuation

AbbVie's shares are up 23.4% in the past six months and 27.1% over the trailing 12-month period. Stocks in the Zacks sub-industry are up 20.4%, while those in the sector are up 12.6% in the past six months. Over the past year, the Zacks sub-industry is up 16.1% while the sector is up 4.6%.

The S&P 500 Index has risen 15.7% in the past six months and 15.9% in the past year.

The stock is currently trading at 15.95X forward 12-month earnings per share, which compares to 17.4X for the Zacks sub-industry, 21.18X for the Zacks sector and 23.3X for the S&P 500 Index.

Over the past five years, the stock has traded as high as 17.7X and as low as 7.85X, with a 5-year median of 13.50X. Our Neutral recommendation indicates that the stock will perform in-line with the market. Our \$240.0 price target reflects 16.7X forward 12-month earnings per share.

The table below shows summary valuation data for ABBV.

Valuation Multiples - ABBV					
		Stock	Sub-Industry	Sector	S&P 500
P/E F12M	Current	15.95	17.4	21.18	23.3
	5-Year High	17.7	20.8	23.59	23.78
	5-Year Low	7.85	13.09	17.84	15.73
	5-Year Median	13.5	16.07	20.62	21.22
P/S F12M	Current	6.04	7.36	2.16	5.27
	5-Year High	6.64	8.1	3.41	5.5
	5-Year Low	3.18	4.64	2.02	3.82
	5-Year Median	4.95	6.14	2.65	5.04
P/B TTM	Current	N/A	8.02	4.03	8.54
	5-Year High	N/A	10.98	6.09	9.15
	5-Year Low	N/A	5.56	3.58	6.59
	5-Year Median	17.59	7.42	4.54	8.04

As of 12/23/2025

Source: Zacks Investment Research

Industry Analysis⁽¹⁾ Zacks Industry Rank: Bottom 25% (182 out of 243)



Top Peers⁽¹⁾

Company (Ticker)	Rec	Rank
AstraZeneca PLC (AZN)	Neutral	3
Bayer Aktiengesellsc...(BAYRY)	Neutral	3
Eli Lilly and Compan...(LLY)	Neutral	3
Merck & Co., Inc. (MRK)	Neutral	3
Novartis AG (NVS)	Neutral	3
Pfizer Inc. (PFE)	Neutral	3
Sanofi (SNY)	Neutral	3
Roche Holding AG (RHHBY)	Underperform	4

Industry Comparison⁽¹⁾ Industry: Large Cap Pharmaceuticals

	ABBV	X Industry	S&P 500	BAYRY	MRK	PFE
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral	Neutral	Neutral
Zacks Rank (Short Term)	3	-	-	3	3	3
VGM Score	D	-	-	A	A	B
Market Cap	406.46 B	265.03 B	39.23 B	41.50 B	265.03 B	142.65 B
# of Analysts	11	4.5	22	2	9	8
Dividend Yield	2.85%	1.87%	1.4%	0.22%	3.18%	6.86%
Value Score	C	-	-	A	A	A
Cash/Price	0.01	0.04	0.04	0.15	0.07	0.10
EV/EBITDA	32.52	12.09	14.67	7.22	11.74	12.31
PEG Ratio	1.25	1.64	2.24	5.27	1.02	NA
Price/Book (P/B)	NA	5.72	3.34	1.20	5.14	1.53
Price/Cash Flow (P/CF)	15.40	13.01	15.39	2.79	11.28	5.75
P/E (F1)	21.61	14.71	19.90	7.49	11.90	8.08
Price/Sales (P/S)	6.81	4.57	3.12	0.82	4.13	2.27
Earnings Yield	4.63%	6.79%	5.01%	13.35%	8.41%	12.36%
Debt/Equity	-24.23	0.52	0.56	1.04	0.77	0.62
Cash Flow (\$/share)	14.93	5.33	8.98	3.79	9.47	4.36
Growth Score	C	-	-	A	B	C
Hist. EPS Growth (3-5 yrs)	-4.06%	1.54%	8.16%	-8.33%	-0.52%	-9.52%
Proj. EPS Growth (F1/F0)	5.14%	14.44%	8.50%	2.92%	17.39%	-0.32%
Curr. Cash Flow Growth	-7.31%	-3.04%	6.86%	-15.66%	210.59%	47.15%
Hist. Cash Flow Growth (3-5 yrs)	11.54%	4.00%	7.48%	2.78%	7.48%	1.92%
Current Ratio	0.72	1.13	1.18	1.13	1.66	1.28
Debt/Capital	97.78%	38.14%	38.01%	50.97%	43.50%	38.14%
Net Margin	4.00%	26.88%	12.78%	-0.68%	29.63%	15.65%
Return on Equity	3,216.47%	36.97%	17.00%	16.48%	44.54%	20.17%
Sales/Assets	0.44	0.46	0.53	0.43	0.54	0.30
Proj. Sales Growth (F1/F0)	8.00%	7.36%	5.84%	5.20%	1.00%	-2.60%
Momentum Score	F	-	-	A	C	F
Daily Price Chg	0.04%	0.15%	-0.03%	0.28%	0.31%	0.24%
1 Week Price Chg	1.57%	-1.03%	2.29%	-2.15%	0.79%	-2.55%
4 Week Price Chg	1.02%	1.02%	1.72%	20.55%	2.05%	-2.41%
12 Week Price Chg	-2.78%	11.64%	3.20%	24.37%	19.29%	-7.35%
52 Week Price Chg	28.34%	28.34%	14.78%	117.73%	6.92%	-5.53%
20 Day Average Volume	5,186,824	3,152,359	2,745,060	501,256	14,334,301	47,395,704
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
(F1) EPS Est 4 week change	-0.01%	0.00%	0.00%	6.42%	0.00%	-1.75%
(F1) EPS Est 12 week change	-11.36%	-0.33%	0.64%	7.22%	0.58%	-0.33%
(Q1) EPS Est Mthly Chg	-0.07%	-0.04%	0.00%	13.33%	0.23%	-8.27%

Analyst Earnings Model⁽²⁾

AbbVie Inc. (ABBV)

In \$MM, except per share data

	2018A	2019A	2020A	2021A	2022E					2023E				2024E	
	FY	FY	FY	FY	1QA	2QA	3QA	4QE	FY	1QE	2QE	3QE	4QE	FY	FY
FY Ends December 31st	Dec-18	Dec-19	Dec-20	Dec-21	31-Mar-22	30-Jun-22	30-Sep-22	31-Dec-22	Dec-22	31-Mar-23	30-Jun-23	30-Sep-23	31-Dec-23	Dec-23	Dec-24
Income Statement															
Total Revenue	\$32,733.0	\$33,265.6	\$45,784.0	\$56,122.0	\$13,538.0	\$14,583.0	\$14,812.0	\$15,315.7	\$58,248.7	\$13,083.8	\$13,309.7	\$13,048.5	\$13,517.0	\$52,959.0	\$54,532.5
Cost of Sales, Non-GAAP	\$6,362.0	\$5,860.0	\$8,175.0	\$9,425.0	\$2,103.0	\$2,232.0	\$2,167.0	\$2,294.1	\$8,796.1	\$1,977.2	\$2,063.9	\$2,095.2	\$2,124.0	\$8,260.3	\$8,957.8
Cost of Sales, GAAP	\$7,718.0	\$7,439.0	\$15,387.0	\$17,446.0	\$4,052.0	\$4,170.0	\$5,022.0	\$4,650.3	\$17,894.3	\$4,016.5	\$4,111.4	\$4,105.6	\$4,170.5	\$16,404.0	\$16,918.5
Gross Profit, Non-GAAP	\$26,371.0	\$27,405.6	\$37,609.0	\$46,697.0	\$11,435.0	\$12,351.0	\$12,645.0	\$13,021.6	\$49,452.6	\$11,106.6	\$11,245.8	\$10,953.3	\$11,393.0	\$44,698.7	\$45,574.6
Gross Profit, GAAP	\$25,015.0	\$25,826.6	\$30,397.0	\$38,676.0	\$9,486.0	\$10,413.0	\$9,790.0	\$10,665.4	\$40,354.4	\$9,067.3	\$9,198.3	\$8,942.9	\$9,346.5	\$36,555.0	\$37,614.0
Selling, General & Administrative, Non-GAAP	\$6,685.0	\$6,687.0	\$9,803.0	\$11,964.0	\$2,852.0	\$3,035.0	\$3,089.0	\$3,346.0	\$12,322.0	\$3,000.7	\$3,212.6	\$3,246.4	\$3,422.2	\$12,881.8	\$13,402.9
Selling, General & Administrative, GAAP	\$7,399.0	\$6,942.0	\$11,299.0	\$12,349.0	\$3,127.0	\$5,412.0	\$3,304.0	\$3,958.1	\$15,801.1	\$4,100.0	\$4,153.1	\$4,105.7	\$4,350.6	\$16,709.3	\$17,782.9
Research & Development, Non-GAAP	\$5,093.0	\$4,989.0	\$5,830.0	\$6,518.0	\$1,480.0	\$1,607.0	\$1,607.0	\$1,720.8	\$6,414.8	\$1,605.7	\$1,731.9	\$1,738.6	\$1,822.5	\$6,898.7	\$6,957.6
Research & Development, GAAP	\$10,329.0	\$6,407.0	\$6,557.0	\$7,084.0	\$1,497.0	\$1,609.0	\$1,614.0	\$1,721.9	\$6,441.9	\$1,608.0	\$1,737.7	\$1,749.4	\$1,849.8	\$6,944.9	\$7,186.6
Acquired IPR&D & Milestones	\$424.0	\$385.0	\$962.0	\$1,198.0	\$145.0	\$269.0	\$40.0	\$0.0	\$454.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Other Operating Expense/(Income), Net	\$500.0	(\$890.0)	\$0.0	\$432.0	\$0.0	(\$172.0)	\$229.0	\$0.0	\$57.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Total Operating Costs & Expenses, Non-GAAP	\$18,140.0	\$17,536.0	\$23,808.0	\$27,907.0	\$6,435.0	\$6,874.0	\$6,863.0	\$7,360.8	\$27,532.8	\$6,583.6	\$7,008.4	\$7,080.2	\$7,368.6	\$28,040.8	\$29,318.3
Total Operating Costs & Expenses, GAAP	\$26,370.0	\$20,283.0	\$34,441.0	\$38,273.0	\$8,821.0	\$11,288.0	\$10,209.0	\$10,330.2	\$40,648.2	\$9,724.5	\$10,002.1	\$9,960.7	\$10,370.8	\$40,058.2	\$41,888.0
Depreciation	\$471.0	\$464.0	\$666.0	\$803.0	\$198.0	\$203.0	\$181.0	\$212.2	\$794.2	\$177.9	\$189.1	\$179.9	\$188.6	\$735.5	\$777.3
Operating Income, Non-GAAP	\$14,593.0	\$15,730.0	\$21,976.0	\$28,215.0	\$6,958.0	\$7,440.0	\$7,909.0	\$7,954.9	\$30,261.9	\$6,500.2	\$6,301.3	\$5,968.3	\$6,148.3	\$24,918.2	\$25,214.1
Operating Income, GAAP	\$6,383.0	\$12,983.0	\$11,363.0	\$17,924.0	\$4,717.0	\$3,295.0	\$4,603.0	\$4,985.5	\$17,600.5	\$3,359.3	\$3,307.6	\$3,087.8	\$3,146.1	\$12,900.8	\$12,644.5
Interest Expense, Net	\$1,144.0	\$1,197.0	\$2,006.0	\$2,384.0	\$539.0	\$532.0	\$497.0	\$497.0	\$2,065.0	\$512.8	\$480.6	\$454.4	\$479.4	\$1,927.2	\$1,867.4
Net Foreign Exchange Loss	\$24.0	\$42.0	\$80.0	\$51.0	\$25.0	\$47.0	\$36.0	\$33.5	\$141.5	\$28.7	\$32.8	\$35.7	\$37.8	\$133.0	\$119.2
Other Expense (Income), Net, Non-GAAP	(\$32.0)	(\$85.0)	(\$142.0)	(\$166.0)	(\$28.0)	(\$79.0)	(\$120.0)	(\$23.3)	(\$250.3)	(\$21.4)	(\$64.4)	(\$99.3)	(\$16.0)	(\$201.2)	(\$199.8)
Other Expense (Income), Net, GAAP	\$18.0	\$3,006.0	\$5,614.0	\$2,500.0	(\$776.0)	\$1,533.0	(\$330.0)	\$153.3	\$580.3	\$116.2	\$338.5	\$71.9	\$168.4	\$695.1	\$697.8
Pre-Tax Income, Non-GAAP	\$13,457.0	\$14,576.0	\$20,032.0	\$25,946.0	\$6,422.0	\$6,940.0	\$7,496.0	\$7,447.7	\$28,305.7	\$5,982.2	\$5,852.4	\$5,577.5	\$5,647.1	\$23,059.2	\$23,427.3
Pre-Tax Income, GAAP	\$5,197.0	\$8,426.0	\$3,398.0	\$12,989.0	\$4,929.0	\$1,183.0	\$4,400.0	\$4,301.7	\$14,813.7	\$2,703.6	\$2,455.7	\$2,525.7	\$2,460.5	\$10,145.6	\$9,960.1
Income Tax, Non-GAAP	\$1,175.0	\$1,252.0	\$2,245.0	\$3,243.0	\$778.0	\$930.0	\$965.0	\$945.9	\$3,618.9	\$759.7	\$743.3	\$708.3	\$717.2	\$2,928.5	\$2,975.3
Income Tax, GAAP	(\$490.0)	\$544.0	(\$1,224.0)	\$1,440.0	\$436.0	\$255.0	\$448.0	\$903.4	\$2,042.4	\$567.8	\$515.7	\$530.4	\$516.7	\$2,130.6	\$2,091.6
Tax Rate, Non-GAAP	8.7%	8.6%	11.2%	12.5%	12.1%	13.4%	12.9%	12.7%	12.7%	12.7%	12.7%	12.7%	12.7%	12.7%	12.7%
Tax Rate, GAAP	(9.4%)	6.5%	(36.0%)	11.1%	8.8%	21.6%	10.2%	21.0%	21.0%	21.0%	21.0%	21.0%	21.0%	21.0%	21.0%
Net Income Before Non-Controlling Interest, GAAP	\$5,687.0	\$7,882.0	\$4,622.0	\$11,549.0	\$4,493.0	\$928.0	\$3,952.0	\$3,398.3	\$12,771.3	\$2,135.9	\$1,940.0	\$1,995.3	\$1,943.8	\$8,015.0	\$7,868.4
Non-Controlling Interest	\$0.0	\$0.0	\$6.0	\$7.0	\$3.0	\$4.0	\$3.0	\$2.9	\$12.9	\$2.9	\$3.0	\$2.7	\$2.9	\$11.5	\$11.7
Net Income, Non-GAAP	\$12,282.0	\$13,324.0	\$17,781.0	\$22,696.0	\$5,641.0	\$6,006.0	\$6,528.0	\$6,498.9	\$24,673.9	\$5,219.5	\$5,106.2	\$4,866.4	\$4,927.1	\$20,119.2	\$20,440.3
Net Income, GAAP	\$5,687.0	\$7,882.0	\$4,616.0	\$11,542.0	\$4,490.0	\$924.0	\$3,949.0	\$3,395.4	\$12,758.4	\$2,133.0	\$1,937.0	\$1,992.6	\$1,940.9	\$8,003.5	\$7,856.7
Basic Shares Outstanding	1,541.0	1,481.0	1,667.0	1,770.0	1,771.0	1,770.0	1,771.0	1,771.0	1,770.8	1,771.0	1,771.0	1,771.0	1,771.0	1,771.0	1,771.0
Diluted Shares Outstanding	1,546.0	1,484.0	1,673.0	1,777.0	1,778.0	1,776.0	1,776.0	1,776.0	1,776.5	1,776.0	1,776.0	1,776.0	1,776.0	1,776.0	1,776.0
Basic EPS	\$3.67	\$5.30	\$2.73	\$6.48	\$2.52	\$0.52	\$2.22	\$1.92	\$7.18	\$1.20	\$1.09	\$1.13	\$1.10	\$4.52	\$4.44
Diluted EPS, Non-GAAP	\$7.91	\$8.94	\$10.56	\$12.70	\$3.16	\$3.37	\$3.66	\$3.66	\$13.85	\$2.94	\$2.88	\$2.74	\$2.77	\$11.33	\$11.51
Diluted EPS, GAAP	\$3.66	\$5.28	\$2.72	\$6.45	\$2.51	\$0.51	\$2.21	\$1.91	\$7.14	\$1.20	\$1.09	\$1.12	\$1.09	\$4.51	\$4.42
Dividend Per Share	\$3.59	\$4.28	\$4.84	\$5.20	\$1.41	\$1.41	\$1.41	\$1.41	\$5.64	\$1.48	\$1.48	\$1.48	\$1.48	\$5.92	\$6.39

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	C
Growth Score	C
Momentum Score	F
VGM Score	D

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless otherwise indicated in the report's first-page footnote. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts' personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts' compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.